New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
14:32 EDTTRGTTargacept halted for volatility after dropping 16% to $3.71
Targacept's TC-1734 failed in an alzheimer study, The Street's Adam Feuerstein tweeted.
News For TRGT From The Last 14 Days
Check below for free stories on TRGT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 15, 2014
10:28 EDTTRGTHigh option volume stocks
High option volume stocks: TRGT ALB UUP ADHD ROC WWW CTRL KERX IMGN NI
July 14, 2014
15:37 EDTTRGTTargacept resumes trading, down 12% following study failure
Subscribe for More Information
15:13 EDTTRGTTargacept to resume trading at 3:35 pm ET
Subscribe for More Information
15:08 EDTTRGTTargacept confirms Alzheimer’s trial does not show superiority of TC-1734
Targacept announced top-line results from a Phase 2b monotherapy clinical trial of TC-1734 as a treatment for mild to moderate Alzheimer’s disease. In the trial, TC-1734 did not meet the objective of showing superiority to donepezil, the marketed medication most often prescribed for Alzheimer’s disease, after 52 weeks of treatment. The trial did not include a placebo arm and was not designed to determine whether TC-1734 is equivalent to donepezil. The co-primary endpoints for the study were measures of cognitive function and global function. Consistent with previous clinical results, TC-1734 exhibited a benign safety and tolerability profile. Targacept President and CEO Dr. Stephen A. Hill said, “We are disappointed for Alzheimer’s disease patients and their families. We designed a rigorous study to provide a definitive answer on whether TC-1734 could be a better treatment option than the current standard of care in what has been a very difficult disease area for the development of novel therapeutics. Based on these results, we do not intend to invest in further development of TC-1734.” Analyses of the full dataset from the trial are ongoing and Targacept plans to present and publish more detailed results over the coming months, the company said.
15:08 EDTTRGTTargacept does not intend to invest in further TC-1734 development
Subscribe for More Information
15:08 EDTTRGTTargacept confirms Alzheimer’s trial does not show superiority of TC-1734
Subscribe for More Information
14:37 EDTTRGTTargacept Alzheimer's study said to fail, TheStreet's Feuerstein says
Subscribe for More Information
14:36 EDTTRGTTargacept halted for trading following reports of study failure
14:32 EDTTRGTTargacept halted for volatility after dropping 16% to $3.71
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use